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Abstract
Background: the ﬁrst quality of life questionnaire speciﬁc to sarcopenia, the SarQoL®, has recently been developed and
validated in French. To extend the availability and utilisation of this questionnaire, its translation and validation in other lan-
guages is necessary.
Objective: the purpose of this study was therefore to translate the SarQoL® into English and validate the psychometric
properties of this new version.
Design: cross-sectional.
Setting: Hertfordshire, UK.
Subjects: in total, 404 participants of the Hertfordshire Cohort Study, UK.
Methods: the translation part was articulated in ﬁve stages: (i) two initial translations from French to English; (ii) synthesis
of the two translations; (iii) backward translations; (iv) expert committee to compare the backward translations with the ori-
ginal questionnaire and (v) pre-test. To validate the English SarQoL®, we assessed its validity (discriminative power, con-
struct validity), reliability (internal consistency, test–retest reliability) and ﬂoor/ceiling effects.
Results: the SarQoL® questionnaire was translated without any major difﬁculties. Results indicated a good discriminative
power (lower score of quality of life for sarcopenic subjects, P = 0.01), high internal consistency (Cronbach’s alpha of 0.88),
consistent construct validity (high correlations found with domains related to mobility, usual activities, vitality, physical func-
tion and low correlations with domains related to anxiety, self-care, mental health and social problems) and excellent test–
retest reliability (intraclass coefﬁcient correlation of 0.95, 95%CI 0.92–0.97). Moreover, no ﬂoor/ceiling has been found.
Conclusions: a valid SarQoL® English questionnaire is now available and can be used with conﬁdence to better assess the
disease burden associated with sarcopenia. It could also be used as a treatment outcome indicator in research.
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Sarcopenia is a syndrome characterised by progressive and
generalised loss of skeletal muscle mass and strength with a
risk of adverse outcomes such as physical disability, func-
tional decline, depression, falls and death [1–13]. Until now,
the consequences of sarcopenia on quality of life have been
poorly investigated and poorly understood. While there is
no consensus over how to measure and monitor health-
related quality of life (HRQoL), the most commonly
adopted method deﬁned by the World Health Organization
(WHO) as individuals’ perception of their position in life in
the context of the culture and value systems in which they
live and in relation to their goals, expectations, standards
and concerns [14]. Evaluating the impact of sarcopenia on
individuals’ HRQoL with a disease-speciﬁc tool is import-
ant to better detect effect of treatment and observe longitu-
dinal changes of quality of life in subjects suffering from
sarcopenia [15]. Until recently, there were no validated spe-
ciﬁc patient-based instruments for measuring quality of life
in those with sarcopenia [16]. Based on these ﬁndings,
Beaudart et al. [17, 18] developed and validated, in 2015,
the SarQoL® (Sarcopenia and Quality of Life, www.sarqol.
org), a quality of life questionnaire speciﬁc for those diag-
nosed with sarcopenia composed of 22 questions that can
provide more accurate knowledge regarding the impact
of sarcopenia on subjects’ well-being. The SarQoL® has
been developed and validated in French. To extend the
availability and utilisation of this questionnaire, its transla-
tion and validation in other languages is necessary. The pur-
pose of this study was therefore to translate the SarQoL®




The SarQoL® is composed of 22 questions including in
total 55 items rated on a 4-point Likert scale (Appendix 1,
also available on www.sarqol.org; Supplementary data are
available in Age and Ageing online). The questionnaire is
scored, through a scoring algorithm, on 100 points, with
higher scores reﬂecting a better quality of life. Items are
organised into seven domains of HRQoL: domain 1
“Physical and Mental Health”; domain 2 “Locomotion”;
domain 3 “Body Composition”; domain 4 “Functionality”;
domain 5 “Activities of daily living”, domain 6 “Leisure
activities” and domain 7 “Fears”. The SarQoL® is a self-
administrated questionnaire and can be completed in
approximately 10 min.
Participants
The study sample composed of men and women from the
Hertfordshire Cohort Study (HCS) who agreed to partici-
pate in the UK component of the European Project on
Osteoarthritis (EPOSA). The HCS and EPOSA study have
been described in detail previously [19, 20]. Brieﬂy, in con-
junction with the National Health Service Central Registry
and the Hertfordshire Family Health Service Association,
men and women who were born as singleton births
between 1931 and 1939 in Hertfordshire and still lived in
the country during the period 1998–2003 were traced.
Among them, 592 HCS participants were eligible to partici-
pate in EPOSA which started in 2011, of whom 444 (75%)
provided written informed consent to participate in the
study. The mean age of these 222 women and 222 men was
75.2 (2.6) years. They presented a mean body mass index of
28.1 ± 4.6 kg/m² and 20.9% of them presented two or
more chronic diseases. All demographic, health, social and
psychological characteristics have been fully described pre-
viously [20].
Procedures
English translation of the SarQoL®
The translation was performed according to translation
guidelines [2]. Five different phases were followed: (i) the
initial translation from French to English by two independ-
ent bilingual translators which were English native speakers;
(ii) the synthesis of the ﬁrst two translations to provide a
single “version 1” of the translated questionnaire; (iii) the
backward translation by two independent bilingual blinded
to the original French version and having French as their
ﬁrst language; (iv) an expert committee review to compare
the backward translations with the original questionnaire
and consent on a “version 2” of the translated question-
naire; (v) the pre-test of the “version 2” of the SarQoL® to
ensure good comprehension of each question of the ques-
tionnaire and conclude with the “version 3”, ﬁnal version
of the English SarQoL®.
Psychometric validation of the English version of the SarQoL®
The methodology applied for the validation of the French
version of the SarQoL® was followed and completed in
two steps. All of the analyses described below were per-
formed using IMB SPPS Statistics 21.0. Results were con-
sidered statistically signiﬁcant at the 5% critical level
(P < 0.05).
(1) In the ﬁrst step, the SarQoL® questionnaire was sent to
the whole sample of participants in order to assess the
discriminative power of the SarQoL®, its internal con-
sistency and the presence of ﬂoor and ceiling effects.
(A) Discriminative power For the discriminative power of
the questionnaire, it was assumed that QoL is bet-
ter in subjects without a diagnosis of sarcopenia
compared to subjects diagnosed sarcopenic. We
used the deﬁnition of the European Working
Group on Sarcopenia in Older People (EWGSOP)
for the diagnosis of sarcopenia [9]. The EWGSOP
recommends using the presence of both low mus-
cle mass and low muscle function (strength or per-
formance) for the diagnosis of sarcopenia.












Therefore, a body composition dual-energy X-ray
absorptiometry scan (Hologic Discovery) was per-
formed on participants for assessment of lean mass,
a handgrip dynamometer was used for the assess-
ment of muscle strength and gait speed on a 8-feet
distance was measured for the assessment of phys-
ical performance. An independent sample T-test
was performed to assess the difference of overall
and domain QoL scores between the sarcopenic
subjects and the non-sarcopenic subjects.
(B) Internal consistency Internal consistency is the estima-
tion of the questionnaire homogeneity. To measure
internal consistency, we used Cronbach’s alpha
coefﬁcient. A coefﬁcient value greater than 0.70
indicates a high level of internal consistency [21].
The impact of each domain on the reliability was
also considered. Normality of quantitative variables
was tested by the Shapiro–Wilk test. Since scores
from the SarQoL® questionnaire were normally
distributed, the correlation of each domain with the
total score of the SarQoL® was also assessed using
Pearson’s correlations.
(C) Floor and ceiling effects Floor and ceiling effects were
deﬁned when a high percentage of the population
had the lowest or the highest score, respectively.
Floor and ceiling effects higher than 15% were
considered to be signiﬁcant [22].
(2) In a second step, the construct validity and the test–
retest reliability of the SarQoL® was determined. These
analyses should ideally be performed on subjects with
sarcopenia. However, when using the deﬁnition of the
EWGSOP [9] to identify sarcopenic subjects in the
sample, only a restricted number of sarcopenic subjects
(n = 14) were identiﬁed. This small sample was insufﬁ-
cient to achieve the recommendations; at least 50 sub-
jects are necessary for these validation analyses [22].
Therefore, modiﬁed cut-offs from those proposed by
the EWGSOP were used to deﬁne a larger group of
subjects, not with sarcopenia itself, but with a low glo-
bal “muscle function”. The participants were selected
by applying the following formula: lowest sex-speciﬁc
half of appendicular muscle mass + (lowest sex-speciﬁc
half of muscle strength or lowest half gait speed). With
this method, 93 subjects were identiﬁed with low “mus-
cle function”. The 93 participants received an envelope
containing twice the SarQoL® questionnaire (SarQoL®
1 and SarQoL® 2) as well as the generic Short Form-36
questionnaire [23] and the the EuroQoL 5-dimension
(EQ-5D) questionnaire [24]. They completed ﬁrst one
SarQoL® as well as the SF-36 and the EQ-5D ques-
tionnaires, for the measurement of the construct valid-
ity, and were invited to respect a 2-week interval before
completing the second SarQoL®, for the measurement
of test–retest reliability.
(A) Construct validity The construct validity was investi-
gated by measuring using the convergent and diver-
gent validity. The correlation between the SarQoL®
and other questionnaires or domains of question-
naires which were supposed to have similar dimen-
sion (convergent validity) or different dimension
(divergent validity) was assessed. Therefore, beside
completing the SarQoL®, the participants were also
asked to complete the SF-36 questionnaire [23]
which is composed of 36 items measuring 8
HRQoL domains (physical functioning, role limita-
tion due to physical problems, bodily pain, general
health, vitality, social functioning, role limitation due
to emotional problem and mental health).
Additionally participants were also asked to com-
plete the EQ-5D questionnaire [24] which records
the level of self-reported problems according to ﬁve
dimensions (mobility, self-care, usual activities,
pain/discomfort and anxiety/depression), with
each dimension having three levels: no problems,
some problems and extreme problems. Data of the
SF-36 and the EQ-5D questionnaires were not nor-
mally distributed and we used therefore Spearman’s
correlations to measure to correlation of the total
score of the SarQoL® with the different scales of
the SF-36 questionnaire as well as with the utility
score of the EQ-5D questionnaire and the individ-
ual domains of the EQ-5D questionnaire.
(B) Test–retest reliability The intraclass coefﬁcient correl-
ation (ICC) was used to test the reliability between
the ﬁrst and second questionnaires overall and indi-
vidual domain scores of the SarQoL®. An ICC over
0.7 was considered as an acceptable reliability [22].
All participants were questioned about having any
health change during the past 2 weeks. The results
of the participants who did not report any health




The 22 questions of the SarQoL® questionnaire were trans-
lated without any major difﬁculties. Some discussions were
however encountered regarding the choice of responses dis-
played for the 4-likert scale. A pre-test was performed on
10 subjects. Minor changes were consequently made to the
questionnaire “version 2”. These changes, which did not
modify the meaning of the sentences, were mainly related
to choice of words used for the 4-Likert scale choices.
Psychometric quality analyses
(1) In the ﬁrst step, the SarQoL® was sent to a sample of
401 participants of the EPOSA. A total of 315 partici-
pants completed the questionnaire; 18 questionnaires
(5.7%) comprised more than 20% of missing data and
were excluded from analyses. Therefore, 297 question-
naires were used (Figure 1). The population sample was












composed of 297 subjects, 137 women (46.1%) and
160 men (53.9%) with a mean age of 79.5 ± 2.62 years.
(A) Discriminant validity Data on muscle mass, muscle
strength and physical performance were only avail-
able for 235 of the 297 respondents. With the cri-
teria and the cut-offs proposed by the EWGSOP [9],
a total of 14 subjects were diagnosed sarcopenic.
Sarcopenic subjects reported a reduced global qual-
ity of life compared to non-sarcopenic subjects
(61.9 ± 16.5 versus 71.3 ± 12.8, P = 0.01). The
domains of physical and mental health, locomotion,
functionality and activities of daily living were also
lower scored in sarcopenic subjects compared to
non-sarcopenic ones (Table 1).
(B) Internal consistency A Cronbach’s alpha of 0.88 was
calculated indicating a high internal consistency.
Deleting the domains one at the time, led to
Chronbach’s alpha values varying between 0.84
(when deleting the domain 5 “Activities of daily liv-
ing”) and 0.89 (for the domain 6 “Leisure activ-
ities”). Moreover, all domains showed a signiﬁcant
positive correlation with the total score of the
SarQoL® ranging from r = 0.51, P < 0.001
(domain 6 versus total score of the SarQoL®) to
0.92, P < 0.001 (domain 4 versus total score of the
SarQoL®) (Table 2).
(C) Floor and ceiling effects No subjects presented with the
lowest score to the questionnaire (0 point) or the
maximal score (100 points). Therefore, no ﬂoor
neither ceiling effects were found for the
questionnaire.
(2) In a second step, the SarQoL® was sent to the 93 parti-
cipants identiﬁed as having a low muscle function. A
total of 88 questionnaires were completed. One of the
Figure 1. Flowchart of the validation study of the English version of the SarQoL®. SarQoL®1 refers to the ﬁrst SarQoL® used
for the “test” and SarQoL®2 refers to the second SarQoL® used for the retest.












questionnaires comprised more than 20% of missing
data and was excluded from analyses. Therefore, con-
struct validity analyses were performed on 87 question-
naires. For test–retest reliability, 78 questionnaires were
used for the test–retest reliability analysis (Figure 1).
(A) Construct validity Results of construct validity are
available in Table 2. As expected, strong/good cor-
relations were found between the SarQoL® and
some domains of the SF-36 questionnaire which
were supposed to have similar dimensions such as
physical functioning (r = 0.82, P < 0.001), vitality
(r = 0.74, P < 0.001) and role limitation due to
physical problems (r = 0.54, P < 0.001) as well as
with the utility score of the EQ-5D questionnaire
(r = 0.58, P < 0.001) and the questions of the EQ-
5D questionnaire related to mobility (r = −0.56,
P < 0.001) and usual activities (r = −0.55,
P < 0.001). We found weaker correlations between
domains of the SarQoL® which were supposed to
have different dimensions such as the domain of
mental health (r = 0.29, P = 0.007), and the
domain of role limitation due to social problems of
the SF-36 questionnaire (r = 0.22, P = 0.04), the
questions related to self-care of the EQ-5D ques-
tionnaire (r = −0.24, P = 0.032) and the questions
related to anxiety of the EQ-5D questionnaire
(r = −0.32, P = 0.004).
(B) Test–retest reliability Excellent agreement was found
between the test and the retest with an ICC of 0.95
(95% CI 0.92–0.97). For individual domains, the
lowest ICC was found for domain 6 (ICC of 0.78,
95%CI 0.58–0.88) which is however still consid-
ered as acceptable.
Discussion
The SarQoL® is the ﬁrst developed quality of life question-
naire speciﬁc to sarcopenia. Because the SarQoL® has only
been developed and validated in French, this study aimed to
provide an English version of the SarQoL® questionnaire,
validated to be used for research and clinic in English-
speaking countries. This research has produced an English
version of the SarQoL® which, after transcultural adaptation
and validation has proven to be a discriminant, valid and reli-
able tool to assess quality of life in subjects with sarcopenia.
To provide equivalence between the French and the
English version of the SarQoL®, a rigorous translation and
cross-cultural adaptation processes was followed. Proof of
correctness and equivalence between the two questionnaires
was provided by the high internal consistency of the trans-
lated questionnaire, by its consistent construct validity and
the excellent test–retest reliability observed in results.
The psychometric properties analyses showed that the
English version of the questionnaire is able to discriminate
the sarcopenic subjects from the non-sarcopenic subjects.
General quality of life seems better for the HCS participants
compared to the Belgian population (54.7 (45.9–66.3) for
the total score of the SarQoL® for Belgian sarcopenic indi-
viduals compared to 61.9 ± 16.5 for the HCS population).
But in both cases, quality of life of sarcopenic subjects was
lower than non-sarcopenic subjects. It has to be pointed
that, during the development of the SarQoL® question-
naire, only questions related to sarcopenia have been
included. Because each question is related to sarcopenia, it
is therefore not surprising to ﬁnd a lower quality of life for
sarcopenic subjects. The English SarQoL® has also been
shown to have a high internal consistency (Cronbach’s alpha
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2. Correlations of the total score of the SarQoL®
questionnaire with individual domains of the SarQoL®, the
SF-36 questionnaire and the EQ-5D questionnaire
Total score of the
SarQoL, r
P-value
SarQoL D1 Physical and Mental Health 0.84a <0.001
SarQoL D2 Locomotion 0.85a <0.001
SarQoL D3 Body Composition 0.61a <0.001
SarQoL D4 Functionality 0.92a <0.001
SarQoL D5 Activities of daily living 0.94a <0.001
SarQoL D6 Leisure activities 0.51a <0.001
SarQoL D7 Fears 0.54a <0.001
Convergent validity
SF-36 physical functioning 0.82b <0.001
SF-36 role limitation due to
physical problems
0.54b <0.001
SF-36 bodily pain 0.55b <0.001
SF-36 general health 0.49b <0.001
SF-36 vitality 0.74b <0.001
EQ-5D utility score 0.58b <0.001
EQ-5D mobility −0.56b <0.001
EQ-5D usual activities −0.55b <0.001
Divergent validity
SF-36 social functioning 0.47b <0.001
SF-36 role limitation due to
emotional problem
0.22b 0.04
SF-36 mental health 0.29b 0.007
EQ-5D, self-care −0.24b 0.032
EQ-5D pain/discomfort −0.41b <0.001
EQ-5D anxiety/depression −0.32b 0.004
aPearson’s correlations (scores of the SarQoL® questionnaire normally
distributed).
bSpearman’s correlations (data of the SF-36 and the EQ-5D questionnaires
not normally distributed).
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .








Total score 61.9 ± 16.5 71.3 ± 12.8 0.01
D1 Physical and Mental Health 60.9 ± 15.5 71.1 ± 13.9 0.01
D2 Locomotion 57.1 ± 14.9 65.9 ± 15.9 0.04
D3 Body Composition 70.4 ± 14.9 71.9 ± 13.3 0.70
D4 Functionality 68.0 ± 18.7 76.5 ± 14.1 0.03
D5 Activities of daily living 55.9 ± 25.7 70.6 ± 13.3 0.002
D6 Leisure activities 43.9 ± 16.8 45.1 ± 18.6 0.81
D7 Fears 88.4 ± 12.5 91.3 ± 12.1 0.39












of 0.88) which is identical to the French version. Moreover,
it appears that the deletion of one domain at a time did not
have a particular impact on the reliability. The construct val-
idity analyses have also showed that the SarQoL® question-
naire was strongly and signiﬁcantly correlated with some
domains of quality of life which were supposed to have
similar dimension, such as mobility, usual activities, vitality,
physical functioning and ﬁnally physical problems. Because
the SarQoL® contains questions speciﬁc to sarcopenia and
then related to muscle function, these results were expected
and can conﬁrm the convergent validity of the SarQoL®.
Moreover, we also found low correlations between the
SarQoL® and some dimensions such as self-care, anxiety,
mental health and social problems, which can conﬁrm that
the SarQoL® is divergent with domains that are supposed
to be divergent. Finally, the test–retest reliability has been
found to be excellent, both for the total score (0.95 (95%
CI 0.92–0.97), which is more or less similar to the French
version 0.91 (95% CI 0.82–0.95)) and for the individual
domains of the SarQoL®. The SarQoL® seems to be stable
across time when no health changes occurred.
This study has some limitations. First of all, our sample
only comprises 14 sarcopenic subjects which led to altera-
tions to our validation analyses. For the question of feasibil-
ity, modiﬁed cut-offs for the EWGSOP deﬁnition were
used to deﬁne a larger group of subjects with impaired
muscle function. Therefore, this population does not reﬂect
exactly a sarcopenic population but is likely to be those
with the lowest muscle function within the study group
based on the same characteristics. A second limitation is
related to the fact that sensitivity to change could not have
been measured in our study given its cross-sectional design.
However, we aim to test the sensitivity to change in further
analyses when prospective data about muscle mass, muscle
strength and physical performance are available for the
EPOSA participants.
In conclusion, a valid SarQoL® English questionnaire
is now available and can be used with conﬁdence to
understand better the burden of disease with sarcopenia
and as a treatment outcome indicator in research. Before
this study, the SarQoL® questionnaire had only been vali-
dated in one unique population study. With this study, we
validated it in a second cohort from a different country.
The psychometric properties indicated that the English
version of the SarQoL® is valid, consistent and reliable
which strengthens the evidence that the SarQoL® is a
strong and valid tool for the assessment of quality of life
in a sarcopenic population. Following the success of this
study, we plan to go on to translate and validate the
SarQoL® in other languages.
Key points
• A disease-speciﬁc tool is important to better detect effect
of treatment and observe longitudinal changes of quality
of life in subjects suffering from sarcopenia.
• The English version of the SarQoL® has been developed
and is valid, consistent and reliable.
• An English version of the SarQoL® is available and can
be used to better assess the disease burden associated
with sarcopenia.
• The SarQoL® questionnaire is available online www.sarqol.
org
Supplementary data
Supplementary data mentioned in the text are available to
subscribers in Age and Ageing online.
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